BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23340058)

  • 1. Multidetector-row computed tomography assessment of adding budesonide/formoterol to tiotropium in patients with chronic obstructive pulmonary disease.
    Yasui H; Inui N; Furuhashi K; Nakamura Y; Uto T; Sato J; Yasuda K; Takehara Y; Suda T; Chida K
    Pulm Pharmacol Ther; 2013 Jun; 26(3):336-41. PubMed ID: 23340058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
    Bölükbas S; Eberlein M; Eckhoff J; Schirren J
    Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
    Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
    Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical trough effects of triple therapy with budesonide/formoterol and tiotropium bromide on pulmonary function outcomes in COPD.
    Williamson PA; Short PM; Clearie KL; Vaidyanathan S; Fardon TC; Howaniec LJ; Lipworth BJ
    Chest; 2010 Sep; 138(3):595-604. PubMed ID: 20418370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J; Akitsu K
    Pulm Pharmacol Ther; 2015 Feb; 30():128-33. PubMed ID: 25183687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, physiological, and radiological features of asthma-chronic obstructive pulmonary disease overlap syndrome.
    Suzuki T; Tada Y; Kawata N; Matsuura Y; Ikari J; Kasahara Y; Tatsumi K
    Int J Chron Obstruct Pulmon Dis; 2015; 10():947-54. PubMed ID: 26028967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives.
    Mittmann N; Hernandez P; Mellström C; Brannman L; Welte T
    Pharmacoeconomics; 2011 May; 29(5):403-14. PubMed ID: 21504240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study.
    Di Marco F; Verga M; Santus P; Morelli N; Cazzola M; Centanni S
    Respir Med; 2006 Nov; 100(11):1925-32. PubMed ID: 16626956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation.
    Santus P; Centanni S; Verga M; Di Marco F; Matera MG; Cazzola M
    Respir Med; 2006 Jul; 100(7):1277-81. PubMed ID: 16337781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients.
    Hoshino M; Ohtawa J
    Respirology; 2014 Apr; 19(3):403-10. PubMed ID: 24708031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
    Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
    Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
    Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
    Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD.
    Hasegawa M; Makita H; Nasuhara Y; Odajima N; Nagai K; Ito Y; Betsuyaku T; Nishimura M
    Thorax; 2009 Apr; 64(4):332-8. PubMed ID: 19074932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.
    Kern DM; Williams SA; Tunceli O; Wessman C; Zhou S; Pethick N; Elhefni H; Trudo F
    Int J Chron Obstruct Pulmon Dis; 2014; 9():775-83. PubMed ID: 25071369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
    Fukuchi Y; Samoro R; Fassakhov R; Taniguchi H; Ekelund J; Carlsson LG; Ichinose M
    Respirology; 2013 Jul; 18(5):866-73. PubMed ID: 23551359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD.
    Cazzola M; Di Marco F; Santus P; Boveri B; Verga M; Matera MG; Centanni S
    Pulm Pharmacol Ther; 2004; 17(1):35-9. PubMed ID: 14643169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
    van Noord JA; Aumann JL; Janssens E; Verhaert J; Smeets JJ; Mueller A; Cornelissen PJ
    Chest; 2006 Mar; 129(3):509-17. PubMed ID: 16537846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD.
    Morgan AR; Parker GJ; Roberts C; Buonaccorsi GA; Maguire NC; Hubbard Cristinacce PL; Singh D; Vestbo J; Bjermer L; Jögi J; Taib Z; Sarv J; Bruijnzeel PL; Olsson LE; Bondesson E; Nihlén U; McGrath DM; Young SS; Waterton JC; Nordenmark LH
    Eur J Radiol; 2014 Nov; 83(11):2093-101. PubMed ID: 25176287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed tomography assessment of pharmacological lung volume reduction induced by bronchodilators in COPD.
    Tanabe N; Muro S; Oguma T; Sato S; Kiyokawa H; Takahashi T; Kudo M; Kinose D; Kubo T; Hoshino Y; Ogawa E; Hirai T; Mishima M
    COPD; 2012 Aug; 9(4):401-8. PubMed ID: 22509949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.